Enovis Corporation (ENOV)
NYSE: ENOV · Real-Time Price · USD
31.30
-0.75 (-2.34%)
May 30, 2025, 4:00 PM - Market closed
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 4, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Total Prevention & Recovery | 1.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Prevention & Recovery Growth | 2.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Reconstructive | 1.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Reconstructive Growth | 41.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Technology | 2.15B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Technology Growth | 18.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Bracing & Support | 479.83M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Bracing & Support Growth | 5.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Other P&R | 271.01M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Other P&R Growth | -1.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International P&R | 360.69M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International P&R Growth | 1.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Reconstructive | 519.76M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Reconstructive Growth | 16.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Reconstructive | 518.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Reconstructive Growth | 81.68% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| Total Medical Technology Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Technology Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevention & Recovery Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevention & Recovery Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 4, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Prevention & Recovery Adjusted EBITDA | 162.58M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevention & Recovery Adjusted EBITDA Growth | 5.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Adjusted EBITDA | 229.88M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Adjusted EBITDA Growth | 62.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 4, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| United States | 1.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 7.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Foreign Locations | 879.59M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Foreign Locations Growth | 37.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|